CD274 and lung carcinoma: An anti-PD-L1 antibody that blocks PD-L1 on the surface of tumor cells is also being investigated for SCCHN management, but durvalumab, and anti-PD-L1 antibody which had already been approved to treat lung cancers [54, 55] did not succeed in showing a significant survival benefit for patients with recurrent/metastatic SCCHN in a phase 3 trial [56].